Empowered Funds LLC Purchases Shares of 2,325 Krystal Biotech, Inc. $KRYS

Empowered Funds LLC purchased a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 2,325 shares of the company’s stock, valued at approximately $864,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Royal Bank of Canada lifted its holdings in shares of Krystal Biotech by 145.2% during the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after acquiring an additional 964 shares during the period. AQR Capital Management LLC raised its stake in shares of Krystal Biotech by 29.9% in the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after acquiring an additional 2,792 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Krystal Biotech by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after acquiring an additional 688 shares during the last quarter. Cetera Investment Advisers raised its position in Krystal Biotech by 107.9% in the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock valued at $597,000 after purchasing an additional 2,255 shares during the last quarter. Finally, Guggenheim Capital LLC boosted its stake in Krystal Biotech by 46.0% in the second quarter. Guggenheim Capital LLC now owns 6,062 shares of the company’s stock worth $833,000 after purchasing an additional 1,909 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

KRYS has been the topic of several research reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a research note on Monday, July 13th. HC Wainwright increased their price target on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research note on Tuesday, June 16th. Royal Bank Of Canada initiated coverage on Krystal Biotech in a report on Friday, August 14th. They issued an “outperform” rating and a $400.00 price objective for the company. Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. Finally, Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $365.40.

Krystal Biotech Stock Performance

KRYS opened at $358.24 on Friday. Krystal Biotech, Inc. has a fifty-two week low of $136.73 and a fifty-two week high of $382.54. The company has a market capitalization of $10.60 billion, a P/E ratio of 44.89 and a beta of 0.54. The stock has a fifty day moving average of $349.81 and a 200-day moving average of $307.38.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating the consensus estimate of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The firm had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. On average, equities research analysts predict that Krystal Biotech, Inc. will post 7.48 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. This represents a 1.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Thomas sold 1,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the transaction, the executive vice president directly owned 1,000 shares in the company, valued at approximately $347,270. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 51,000 shares of company stock valued at $17,558,270. 13.10% of the stock is currently owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.